Epigenetic therapies and technologies market will reach $2,518 million in 2013

Monday 4 March 2013, Amsterdam

A new report predicts that the overall world market for epigenetic therapies and technologies will be worth $2,518m in 2013. Between 2011 and 2017, the global market will grow with a CAGR of over 10%. The launch of new products in all market sectors will drive growth during this decade. Those findings, among others, appear in Epigenetic Therapies and Technologies: World Market Prospects 2013-2023, published in January 2013.

Throughout the 10-year forecast period, epigenetic therapies will be the largest sector of the world epigenetics market, accounting for more than half of revenues in 2023. In 2011, Celgene’s Vidaza led the market, with revenue of $705m. Patent expiries and generic launches will affect three of the four currently-marketed therapies by the middle of this decade. Growth in the sector will be driven by the launch of new drugs beyond 2014. Two new epigenetic therapies - TopoTarget/Spectrum Pharmaceuticals’ belinostat and Novartis’ Faridak will reach major markets in that year.

The epigenetic diagnostics submarket will grow fastest between 2013 and 2023. More than ten epigenetic-based diagnostics are marketed in major developed markets, although revenues for these products are low. The launch of in vitro diagnostic tests (IVDs) and companion diagnostics for cancer indications, such as Epigenomics’ Epi proColon 2.0 in the US, will drive growth in this sector to 2023. Strong growth is also forecast for the epigenetic technologies submarket, driven by increased demand for research tools worldwide, with revenues reaching more than $1bn by 2017.

Richard Lang, a pharmaceutical industry analyst, said: “Collaborations between the pharmaceutical industry and academia have led to rapid growth in the understanding of the role of epigenetics in disease. Continued collaboration in global projects mapping epigenomes will lead to further opportunities in drug discovery and diagnostic biomarker development. Licensing deals between multinational pharmaceutical players and small biotechs will accelerate promising drug candidates into late-stage trials during this decade.

“In 2011, the US and Europe dominated the market, accounting for more than 75% of global revenues. The US is the only major national market where all four epigenetic therapies are approved. Emerging markets currently play only a minor role in the global epigenetics industry. However, rising drug sales and greater involvement in global research collaborations will lead to rising revenues there. By 2023, revenues for epigenetic therapies and technologies in the BRIC nations will total $255m.”

Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 provides quantitative and qualitative analyses of the epigenetics market. It shows revenue forecasts to 2023 for the overall world market, submarkets, leading marketed and pipeline therapies, and prominent national and regional markets. It also identifies and discusses future trends in epigenetic research and product development. The study adds to analytical reports covering innovative and emerging sectors of the pharmaceutical industry.